Clarivate Unveils the 2025 Journal Citation Reports
50th Anniversary Year Sees Strengthened Focus on Research Integrity LONDON, June 18,…
Mobile industry emissions down 8%, but pace must double to hit net zero
LONDON, June 18, 2025 /PRNewswire/ -- The mobile industry's operational emissions fell…
The Block Announces Strategic Leadership Evolution as Leading Digital Asset News Platform Enters Next Growth Phase
Larry Cermak transitions to President role to focus on research and product…
Arcontech Excelerator. A performant, stress-free alternative to migrating to LSEG Workspace Excel Add-in
LONDON, June 17, 2025 /PRNewswire/ --Â For the thousands of financial professionals who…
Nokia launches Autonomous Network Fabric to help customers accelerate network automation
Press releaseNokia launches Autonomous Network Fabric to help customers accelerate network automation…
adidas Launches F50 SPARKFUSION A Boot Built by and for Womens Football Players
Designed using adidas’ biggest ever study into the boot requirements of women…
Airsys Receives Frost & Sullivan’s 2025 North America Company of the Year Recognition for Excellence in Data Center Thermal Management
The recognition showcases Airsys's groundbreaking advancements in energy-efficient cooling, thermal innovation, and…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
June 14, 2025 10:48 ET Â | Source: Celldex Therapeutics, Inc. 77% of…